Keywords:
gastric cancer, molecular profiling, precision oncology, biomarkers, HER2, PD-L1 CPS, MSI-H dMMR, CLDN18.2, immunotherapy, targeted therapy.References
Ajani J. A., et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines in Oncology. Practice Guideline. 2025.
Lordick F., Carneiro F., Cascinu S., et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2022;33(10):1005–1020. doi: 10.1016/j.annonc.2022.07.004.
The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. Published 23 July 2014. doi: 10.1038/nature13480.
Al-Batran S.-E., Homann N., Pauligk C., et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma FLOT4: a randomised, phase 2/3 trial. The Lancet. 2019.
Janjigian Y. Y., Shitara K., Moehler M., et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma CheckMate 649: a randomised, open-label, phase 3 trial. The Lancet. 2021. doi: 10.1016/S0140-6736(21)00797-2.
Janjigian Y. Y., Kawazoe A., Yañez P., et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. 2023.
Shitara K., Bang Y.-J., Iwasa S., et al. Trastuzumab deruxtecan in previously treated HER2 -positive gastric cancer. The New England Journal of Medicine. 2020;382:2419–2430. doi: 10.1056/NEJ Moa2004413.
Shitara K., Özgüroğlu M., Bang Y.-J., et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma SPOTLIGHT: a multicentre, randomised, double-blind, phase 3 trial. 2023.